Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
This study is ongoing, but not recruiting participants.
Sponsor:
SK Life Science
Information provided by (Responsible Party):
SK Life Science
ClinicalTrials.gov Identifier:
NCT01397968
First received: July 18, 2011
Last updated: March 11, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is to evaluate the efficacy of YKP3089 in reducing seizure frequency when compared to baseline in subjects with partial onset seizures not fully controlled despite their treatment with 1 to 3 concomitant anti-epileptic drugs.
Also to evaluate the safety and tolerability of YKP3089.
| Condition | Intervention | Phase |
|---|---|---|
|
Partial Epilepsy |
Drug: YKP3089 Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Phase 2 Multicenter, Double-Blind, Randomized, Adjunctive Placebo Controlled Trial to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures |
Resource links provided by NLM:
Genetics Home Reference related topics:
autosomal dominant partial epilepsy with auditory features
pyridoxal 5'-phosphate-dependent epilepsy
U.S. FDA Resources
Further study details as provided by SK Life Science:
Primary Outcome Measures:
- Percent change in seizure frequency per 28 days in the Treatment Period compared to the Baseline in the Intention to Treat (ITT) Population. [ Time Frame: per 28 days during 12 week treatment period ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Responder rate: An analysis of subjects who experience a 50% or greater reduction in seizure frequency in the Treatment Period of the Double-blind Phase. [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 200 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | July 2013 |
| Estimated Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: YKP3089 |
Drug: YKP3089
Capsule, dose to be titrated
|
|
Placebo Comparator: Placebo
Placebo capsule
|
Drug: Placebo
Placebo capsule
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of treatment resistant partial epilepsy;
- History of epilepsy for at least 2 years;
- Have at least 3 simple partial with motor component, complex partial or secondarily generalized seizures per month with no consecutive 21 day seizure free period.
Currently treated on a stable dose of :
- 1 - 3 AED's for at least 12 weeks prior to randomization.
- VNS will not be counted as AED; however the parameters must remain stable for at least 4 weeks prior to baseline.
- Benzodiazepines taken at least once per week for epilepsy, or for anxiety or sleep disorder, will be counted as 1 AED. Therefore only a maximum of two additional approved AEDs will be allowed.
Exclusion Criteria:
- A history of alcoholism, drug abuse, or drug addiction within the past 2 years.
- Subject has had status epilepticus within past 1 year.
- Subject has had greater than 2 allergic reactions to an AED or one serious hypersensitivity reaction to an AED.
- Subjects taking felbamate with less than 18 months continuous exposure.
- Subjects receiving phenytoin, phenobarbitone or metabolites of these drugs.
- No active suicidal plan/intent or active suicidal thoughts in the past 6 months.
- History of suicide attempt in the last 2 years; not more than 1 lifetime suicide attempt.
- Subject meets criteria for current major depressive episode (within 6 months).
- Use of intermittent rescue benzodiazepines more than once/month (1-2 doses in a 24-hour period is considered one rescue) in the one month period prior to Visit 1.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01397968
Hide Study Locations
Hide Study LocationsLocations
| United States, Arizona | |
| St. Joseph Hospital & Medical Center/Barrow Neurology Clinic | |
| Phoenix, Arizona, United States, 85013 | |
| United States, Arkansas | |
| Clinical Trials, Inc. | |
| Little Rock, Arkansas, United States, 72205 | |
| United States, California | |
| Kaiser Permanente | |
| Aneheim, California, United States, 92806 | |
| VA Greater Los Angeles Healthcare System | |
| Los Angeles, California, United States, 90073 | |
| United States, Florida | |
| Bradenton Research Center, Inc. | |
| Bradenton, Florida, United States, 34205 | |
| United States, Kentucky | |
| Bluegrass Epilepsy Research, LLC | |
| Lexington, Kentucky, United States, 40504 | |
| United States, Maryland | |
| John's Hopkins University School of Medicine | |
| Baltimore, Maryland, United States, 21287 | |
| Mid-Atlantic Epilepsy and Sleep Center | |
| Bethesda, Maryland, United States, 20817 | |
| United States, Missouri | |
| The Comprehensive Epilepsy Care Center for Children & Adults | |
| Chesterfield, Missouri, United States, 63017 | |
| United States, Ohio | |
| Ohio State University Medical Center | |
| Columbus, Ohio, United States, 43210 | |
| The University of Toledo | |
| Toledo, Ohio, United States, 43614 | |
| United States, Oklahoma | |
| Lynn Health Science Institute | |
| Oklahoma City, Oklahoma, United States, 73112 | |
| United States, Pennsylvania | |
| Thomas Jefferson University Comprehensive Epilepsy Center | |
| Philadelphia, Pennsylvania, United States, 19107 | |
| University of Pennsylvania Health System | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| United States, Texas | |
| Neurological Clinic of Texas, P.A. | |
| Dallas, Texas, United States, 75230 | |
| United States, Virginia | |
| University of Virginia | |
| Charlottesville, Virginia, United States, 22903 | |
| India | |
| St. Theresa's General Hospital | |
| Hyderabad, Andhra Pradesh, India, 500 018 | |
| Bangalore Clinisearch | |
| Bangalore, Karnataka, India, 560043 | |
| M.S. Ramaiah Medical College and Hospital | |
| Bangalore, Karnataka, India, 560 054 | |
| Mallikatta Neuro Centre | |
| Mangalore, Karnataka, India, 575 002 | |
| Deenanath Mangeshkar Hospital & Research Centre | |
| Pune, Maharashtra, India, 411004 | |
| Max Super Specialty Hospital | |
| Saket, New Delhi, India, 110 017 | |
| Nightingale Hospital | |
| Kolkata, West Bengal, India, 700 071 | |
| Korea, Republic of | |
| Dong-A University Medical Center | |
| Busan, Korea, Republic of, 602-715 | |
| Keimyung University Dongsan Hospital | |
| Daegu, Korea, Republic of, 700-712 | |
| Chungnam National University Hospital | |
| Daejeon, Korea, Republic of, 301-721 | |
| Hallym University Sacred Heart Hospital | |
| Gyeonggi-do, Korea, Republic of, 431-070 | |
| Asan Medical Center | |
| Seoul, Korea, Republic of, 138-736 | |
| Seoul National University Hospital | |
| Seoul, Korea, Republic of, 110-744 | |
| Samsung Medical Center | |
| Seoul, Korea, Republic of, 135-710 | |
| Korea University Anam Hospital | |
| Seoul, Korea, Republic of, 136-705 | |
| Poland | |
| NZOZ Vito-Med Sp. Zo.o | |
| Gliwice, Poland, 44-100 | |
| SPSK Nr 7 SUM w Katowicach, Gornoslaskie CM im. Prof. Leszka Gieca | |
| Katowice, Poland, 40-635 | |
| NZOZ Diagnomed | |
| Katowice, Poland, 40-594 | |
| Malopolskie Centrum Medyczne | |
| Krakow, Poland, 30-510 | |
| Centrum Leczenia Padaczki i Migreny | |
| Krakow, Poland, 31-209 | |
| Centrum Terapii Wspolczesnej | |
| Lodz, Poland, 90-242 | |
| Solumed s.c. | |
| Poznan, Poland, 60-539 | |
Sponsors and Collaborators
SK Life Science
Investigators
| Principal Investigator: | Pavel Klein, MB | Mid-Atlantic Epilepsy and Sleep Center |
More Information
No publications provided by SK Life Science
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | SK Life Science |
| ClinicalTrials.gov Identifier: | NCT01397968 History of Changes |
| Other Study ID Numbers: | YKP3089C013 |
| Study First Received: | July 18, 2011 |
| Last Updated: | March 11, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by SK Life Science:
|
partial onset seizures treatment resistant partial epilepsy |
Additional relevant MeSH terms:
|
Epilepsy Epilepsies, Partial Seizures Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms |
ClinicalTrials.gov processed this record on May 16, 2013